These results suggest that, in prostate cancer, the increase in the fumarate level might trigger carcinogenesis, partly via the HIF1α and NFκB pathways, which have crucial clinical relevance in patients with prostate cancer. The gene discussed is NFKB1; the disease is prostate carcinoma.